Pharmaceutical compositions comprising: (a) a beta-lactam compound selected from sulbactam, cefepime or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

The present invention relates to an improved process for preparing intermediate of Apixaban. The present invention provides an improved process for preparing 1-(4-iodophenyl) piperidine-2-one, which is an intermediate in the synthesis of active substance Apixaban. The product 1-(4-iodophenyl) piperidine-2-one obtain...

The present invention relates to novel stable crystalline form of Vortioxetine Hydrobromide, has purity more than 97 % when measured by HPLC. In particular, of the present invention directs to process for the preparation of novel stable crystalline form of Vortioxetine Hydrobromide, has purity more than 97 % when me...

The invention relates to a composition comprising of bepotastine or pharmaceutically acceptable salt thereof, a corticosteroid or pharmaceutically acceptable salt thereof, wherein the composition is formulated as nasal spray or nasal drop.

ABSTRACT The present invention relates to a process for the preparation of 3-(hydroxymethyl)-6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine of formula II or its salt from 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine or its salt by using formaldehyde ...

The present invention relates to solid oral pharmaceutical composition comprising metformin and linagliptin or salt thereof. In particular, the present invention relates to solid oral stable pharmaceutical composition comprising fixed dose combination of metformin and linagliptin or salt thereof. By using an alkaliz...

The present invention discloses a composition comprising readily dissociable molecular aggregates formed by combining an insulin, insulin analogue, derivative or metabolite having isoelectric point between 5.8 to 8.5 in combination with one or more an insulin, insulin analogue, derivative or metabolite having isoele...

The present invention relates to solid oral pharmaceutical compositions comprising ticagrelor or salts thereof. In particular, the present invention relates to a composition comprising ticagrelor or salts thereof in an amount less than 20 % of the weight of total composition and at least one pharmaceutically accepta...

The present invention provides a chemical process for controlling the particle size of Atovaquone by using acid and base treatment.

ABSTRACT The present invention relates to an improved process for the preparation of intermediate of alcaftadine, 1-(2-Phenylethyl)-1H-imidazole of formula II: Formula II or its salt from (2-chloroethyl)benzene using potassium carbonate.

The present invention relates to a process for the preparation Apixaban Intermediate. The present invention specifically directs to process for the preparation of 3, 3-dichloro-1-(4-iodophenyl) piperidin-2-one or salts thereof. The present invention process is very simple cost effective and may be employed at commer...

The invention relates to a process of preparing a pharmaceutical composition comprising bepotastine or pharmaceutically acceptable salt thereof, cortiocosteroids or pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient, wherein the composition is formulated as nasal spray o...

The invention relates to a process of preparing a pharmaceutical composition comprising bepotastine or pharmaceutically acceptable salt thereof, decongestants and/or cortiocosteroids and at least one pharmaceutically acceptable excipient, wherein the composition is formulated as nasal spray or nasal drop. ...

A pharmaceutical compositions comprising: (a) a carbapenem antibacterial agent selected from imipenem, meropenem, ertapenem, doripenem or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I), or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed. ...

The present invention relates to solid oral pharmaceutical compositions comprising ticagrelor or salts thereof. In particular, the present invention relates to a composition comprising ticagrelor or salts thereof in an amount less than 20 % of the weight of total composition and at least one pharmaceutically accepta...

The present invention relates to a stable pharmaceutical composition comprising metformin and linagliptin or salt thereof. In particular, the present invention relates to solid oral stable pharmaceutical composition comprising fixed dose combination of metformin and linagliptin or salt thereof. By using one or more ...

The present invention relates to solid oral pharmaceutical compositions comprising ticagrelor or salts thereof. In particular, the present invention relates to solid oral pharmaceutical compositions comprising ticagrelor or salts thereof and at least one pharmaceutically acceptable excipient other than water-insolub...

Pure S-(-)-9-fluoro-8-(4-hydroxysulfonyloxy-piperidin-1-yl)-5-methyl-6,7-dihydro -1-oxo-1H, 5H-benzo [i, j] quinolizine-2-carboxylic acid and a process for its preparation is disclosed.

The present invention relates to a process for preparing a solid oral dosage forms comprising effective amounts of fingolimod or salts thereof. In particular, the present invention relates to a process for preparing solid oral dosage forms comprising fingolimod or salts thereof, and other pharmaceutically acceptable...

The present invention relates to solid oral dosage forms comprising fingolimod or salts thereof. In particular, the present invention relates to solid oral dosage forms comprising fingolimod or salts thereof, and other pharmaceutically acceptable excipients. The invention further relates to method of treating multip...

The present invention relates to pharmaceutical compositions comprising roflumilast, acebrophylline and salts thereof. In particular, the present invention relates to solid oral modified-release compositions comprising roflumilast and acebrophylline or salts thereof. The present invention also provides methods of pr...

The present invention relates to a solid oral modified-release composition comprising oxcarbazepine or salts thereof. In particular, the present invention relates to a solid oral modified-release composition comprising matrix of oxcarbazepine or salts thereof with one or more pharmaceutically acceptable excipients; ...

The present invention relates to a process of preparing solid oral modified-release composition comprising oxcarbazepine or salts thereof. In particular, the process involves a step of preparation of a matrix of oxcarbazepine or salts thereof with one or more rate-controlling excipients having pH independent solubil...

The present invention provides a process for the preparation of Sitagliptin or its pharmaceutically acceptable salt. The present invention also provides simple and cost effective process for intermediate of Sitagliptin, 7-[(3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)-butanoyl]-3-(trifluoromet...

A compliance blister package may comprise a planar surface; the planar surface may comprise a matrix of blisters arranged in a plurality of columns and plurality of rows for containing a fixed dosage form; the dosage form may comprise a therapeutically active ingredient for once a day administration; the columns may...

The present invention relates to a process for preparing dimer of zoledronic acid, a pharmaceutically acceptable salt thereof, or a hydrate thereof, which is useful as reference marker. Formula II

A process for 2-oxo-2H-chromen-4-yl-sulphate (referred to as chromen sulphamate comprises) of, c) reaction of 4-hydroxy coumarin in presence of base with chlorosulphonic acid-organic solvent mixture to form 2-oxo-2H-chromen-4-yl-sulphate. d) conversion of 2-oxo-2H-chromen-4-yl-sulphate to 2-oxo—2H-chromen-4-yl-sulph...

The present invention relates to S-(-)-optically pure benzoquinolizine carboxylic acid of formula I, and their pharmaceutically acceptable salts, derivatives, pseudopolymorphs, and hydrates, substantially free of their R-(+)-isomers, to processes for their preparation and to pharmaceutical compositions comprising an...

The present invention relates to process for preparing solid oral pharmaceutical compositions comprising ticagrelor or salts thereof. In particular, the present invention relates to a process for preparing solid oral pharmaceutical compositions comprising ticagrelor or salts thereof and at least one pharmaceutically...

The present invention relates to a process of preparing pharmaceutical compositions of NSAID and PPI or salts thereof. In particular, the invention relates to a process of preparing pharmaceutical compositions of NSAID and PPI or salts thereof comprising a core and two or more layers coated on the core. The inventio...

The present invention relates to an improved process for the preparation of Anagliptin, intermediates thereof, or pharmaceutically acceptable thereof. The invention relates to a process for the preparation of intermediate of compound of formula III:     Formula III and its conversion to Anagliptin or a phar...

The present invention provides a pharmaceutical composition that comprises of pre-coated granules of clopidogrel or salts thereof along with other pharmaceutically acceptable excipients.

A process for preparation of compound of Formula (I) is disclosed.

Compounds of Formula (I) their preparation and use in preventing or treating a bacterial infection are disclosed.

A process for preparing pharmaceutical composition comprising cefdinir or pharmaceutically acceptable salts thereof wherein the said process involves the step of a) granulating cefdinir with suitable solubilization or wetting agent and organic solvent b) blending granules of step a) with pharmaceutically acceptable...

The present invention relates to a process for the preparation of 7-(4-chloro/bromobutoxy)-3,4-dihydrocarbostyril, which is useful as a key intermediate in the preparation of aripiprazole in presence of combination of bases.

The invention relates to crystalline S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i.j]quionlizine-2-carboxylic acid L-arginine salt tetrahydrate, a process for its prpparation and pharmaceutical formulations incorporating it as the active ingredient for use in treating microbial ...

A stable unit-dose combination for the simultaneous delivery of a short-acting oral hypoglycemic biologically active agent (such as, for example, repaglinide or nateglinide), and a long-acting oral hypoglycemic biologically active agent (such as, for example, metformin). Such a composition can be used for the treatm...

Compounds of Formula (I) their preparation and use in preventing or treating a bacterial infection are disclosed.

The present invention relates to optically pure 8-(substituted piperidino)-benzo [i,j] quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and to pharmaceutical compositions comprising 8-(substituted piperidino)-benzo [i,j] ...

The present invention provides an improved process for the preparation of azithromycin of Formula –I wherein the process comprises of, a) reducing 6,9-Imino ether compound of Formula II in water optionally containing an organic solvent while maintaining the pH of 8 or less with a boron containing reducing agent, b) ...

A process for preparation a compound of Formula (II) is disclosed.

The present invention describes a pharmaceutical formulation for gynecological indications in cattle. The formulation comprising a triple combination of three antimicrobial agents-metronidazole, gentamicin and povidone-iodine. Uterine infections in cattle can be caused by a veriety of microorganisms including variou...

The present invention relates to a process of preparing a pharmaceutical composition of metformin and linagliptin or salt thereof. In particular, the present invention relates to a process of preparing stable oral pharmaceutical composition comprising fixed dose combination of metformin and linagliptin or salt there...

A process for preparation of alfuzosin hydrochloride wherein the said process comprises of, a) converting alfuzosin base to alfuzosin hydrochloride alcohol solvate by treating the alfuzosin base crude with alcoholic hydrogen chloride, b) isolating alcohol solvate of alfuzosin hydrochloride by filtration, c) refluxin...

The present invention relates to an efficient process for purification of Zoledronic acid or pharmaceutically acceptable salt thereof. Process for purification of zoledronic acid or salt thereof, wherein the said process comprises of a) adding the hydrochloric acid to aqueous suspension of zoledronic acid, b) adding...

The present invention provides a proved process for the preparation of nizatidine of formula I, wherein the said process comprises of, a) reducing the thiazole ester of formula II to thiazole intermediate of formula III, b) converting thiazole intermediate of formula III to nizatidine

The present invention provides once a day pharmaceutical composition comprising diclofenac sodium in an extended release form and meloxicam in an immediate release form in admixture with pharmaceutically acceptable carrier so as to provide better pain management, reduced side effects and improved patient compliance....

The present invention relates to solid oral pharmaceutical composition comprising metformin and linagliptin or salt thereof. In particular, the present invention relates to solid oral stable pharmaceutical composition comprising fixed dose combination of metformin and linagliptin or salt thereof. By using an alkaliz...

The present invention relates to a process of preparing pharmaceutical compositions of NSAID and PPI or salts thereof. In particular, the invention relates to a process of preparing pharmaceutical compositions of plurality of components of NSAID and PPI or salts thereof. The invention also includes method of treatin...

The present invention provides a process for preparation of compound of Formula I wherein R1 is selected from group consisting of independently H, OCH3 or OCHF2; R2 is selected from group consisting of independently CH3 or OCH3; R3 is selected from group consisting of independently OCH3 or CH2CF3 and O(CH2)3OCH3, ...

The present invention provides for the preparation of Bethanechol chloride, wherein the said process comprises of a) reacting 2-hydroxy propyl trialkyl ammonium halide with triphosgene solution, b) isolating the bethanechol chloride from reaction mass using organic solvent.

The invention discloses compounds of Formula (I), their preparation, and their use in treating a bacterial infection.

A process for the preparation of azithromycin, wherein the process comprises of reducing the compound of formula II with suitable boron reducing agent, (a) extracting the boron complex of compound of Formula III from the reaction mass with suitable organic solvent, treating the organic layer of step b) with a malic ...

The inventions discloses a process for preparation of compounds of Formula (IX), Wherein, R is C1-C6 alkyl, R1 is hydrogen or a hydroxyl protecting group, and R2 is hydrogen or fluorine.

A process for preparation of a compound of Formula (I) is disclosed.

There is provided an aqueous injectable biphasic pharmaceutical composition comprising 200IU/ml of insulin, insulin analogues or derivative thereof, wherein said composition comprises (i) a solution of insulin, insulin analogue or derivative thereof, and (ii) crystals of insulin, insulin analogue or derivative there...

A once-a-day controlled release drug delivery system of diltiazem hydrochloride is provided, which is bioequivalent in plasma profile of Cardizem® CD. The fast, medium, and slow release fractions are prepared using various compositions and weight gains. The individual fill weights are computed and then are filled in...

The degradation mechanism of felodipine in a dosage form environment has been identified as an acid-catalyzed solvolytic oxidation mechanism. Dicalcium 5 phosphate dihydrate was identified as a source of H+ ions which were considered as a catalyst in the oxidation mechanism. The preferred components for preparin...

A foldable compliance blister package may comprise two planar surfaces; planar surfaces may be joined by a strip; one of the planar surfaces may comprise a matrix of blisters arranged in a plurality of columns and plurality of rows for containing fixed dosage form for once a day administration; the other planar surf...

This invention relates to a foldable compliance blister package comprising a matrix of blisters arranged in a plurality of columns and plurality of rows; matrix of blisters in one of the folded planar portions comprise a fixed disease treating dosage form which comprises a therapeutically active ingredient for once ...

A foldable compliance blister package may comprise two planar surfaces; the planar surfaces further may comprise a backing strip; the planar surfaces may be joined by a strip; the planar surfaces may comprise a matrix of blisters arranged in a plurality of columns and plurality of rows; the columns one to four and c...

The lyophilized solid pharmaceutical compositions comprising a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

The present invention relates to a process for the preparation of 3-(4-Chlorobutanoyl)-1H-indole-5-carbonitrile, which is key intermediate for Vilazodone or its pharmaceutically acceptable salt.

Pharmaceutical compositions comprising antibacterial agents selected from cefepime, cefpirome or a pharmaceutically acceptable derivative thereof, and compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.

The present invention relates to an improved process for the preparation of 1-(((2R,3S)-2-(2,5-difluorophenyl)-3-methyloxiran-2-yl)methyl)-1H-1,2,4-triazole. In a particular aspect of the present invention relates to one pot process for the preparation of oxirane intermediate, which is a key intermediate for the pre...

The present invention relates to an improved process for the preparation of (R)-2-(2,5-difluorophenyl)-3-(tetrahydro-2H-pyran-2-yloxy)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol. In a particular aspect of the present invention relates to one pot process for the preparation of triazole intermediate, which is a key intermedi...

The present invention relates to a process for the preparation of Anagliptin or a pharmaceutically acceptable salt thereof. Further, the present invention relates to a polymorph of Anagliptin or a pharmaceutically acceptable salt thereof and a method for the preparation thereof

The present invention provides a process for the purification of crude Regadenoson using suitable solvent at a specific temperature to provide Regadenoson having purity greater than or equal to 99.5%.

Pharmaceutical compositions comprising: (a) at least one cephalosporin antibacterial agent and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

Pharmaceutical compositions comprising ceftibuten or a pharmaceutically acceptable derivative thereof, and clavulanic acid or a pharmaceutically acceptable derivative thereof are disclosed.

A process for preparation of (2S,5R)-N-(2-aminoethoxy)-6-(sulfooxy)-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxamide is disclosed.

Compounds of Formula (I), their preparation, and use in preventing or treating a bacterial infection are disclosed.

The present invention relates to process for the preparation of N-(3,4-dimethoxyphenethyl) formamide. In particular of the present invention relates to the improved process for the preparation of N-(3,4-dimethoxyphenethyl) formamide, wherein water formed during the reaction is removed by azeotropic distillation. ...

The present invention relates to the stable amorphous palonosetron hydrochloride, has purity more than 99 %. In particular of the present invention relates to the process for the preparation of stable amorphous palonosetron hydrochloride using spray dryer, has purity more than 99 %.

The present invention relates to an improved process for the preparation of N-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-5,6,7,8-tetrahydronaphthalene-1-carboxamide. In a particular aspect of the present invention relates to one pot process for the preparation of amide intermediate, which is used as a key intermediate for t...

Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.

Pharmaceutical compositions comprising sulbactam or a pharmaceutically acceptable derivative thereof, and a compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.

The present invention relates to a process for the preparation of aripiprazole from 7-(4-halobutoxy)-3,4-dihydrocarbostyril by using solvent system comprising combination of two or more solvents wherein formation of dimmer impurity is less than 0.15%.

Pharmaceutical compositions comprising cefepime or a pharmaceutically acceptable salt thereof tazobactam or a pharmaceutically acceptable salt thereof and arginine or a pharmaceutically acceptable salt thereof; and their use in treatment control or prevention of bacterial infection is disclosed. ...

There is provided a pharmaceutical composition comprising: (a) insulin glargine, (b) at least two amino acids, and optionally (c) one or more pharmaceutically acceptable excipients. In particular, there is provided a pharmaceutical composition comprising: (a) insulin glargine, (b) arginine and isoleucine in a weight...

The present invention relates to a process for the preparation intermediate of Saxagliptin, amide compound of Formula II, and its conversion to pharmaceutically acceptable salt Saxagliptin. Formula II

The present invention provides a process for preparing paliperidone free from its keto impurity comprising the reaction between 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride and 3-(2-chloroethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one in presence of base and a mixture of a...

The fluid delivery pen of the present invention has a reduced dose setting friction mechanism which may produce a sound of higher audibility for each click corresponding to one unit dose set using a dose setting mechanism and also produces a sound of lower audibility than the former for each click when the set dose ...

The specification discloses crystalline form of Dofetilide, process of its preparation and compositions thereof.

The present invention relates to process of preparing solid oral pharmaceutical compositions comprising cinacalcet or salts thereof. In particular, the present invention relates to process of preparing solid oral pharmaceutical compositions comprising cinacalcet or salts thereof and at least one pharmaceutically acc...

The present invention relates to a process for the preparation of intermediate of azole derivative. Further, the present invention relates to a process for the preparation of (2R)-2’, 5’-Difluoro-2-(3,4,5,6-tetrahydro-2H-pyran-2-yloxy)-propiophenone or a pharmaceutically acceptable slat thereof, which is a key inter...

The present invention relates to oral liquid pharmaceutical compositions comprising methyldopa or salts thereof with enhanced oral bioavailability. In particular, the present invention relates to a pharmaceutical compositions prepared into a soft gelatin capsule containing methyldopa or salts thereof as the active i...

There is provided an improved process for preparing microparticles. More particularly, a process is provided for preparing microparticles having a selected release profile for release of drug contained in the microparticles. By subjecting the emulsion to multiple steps including quenching, fine removal by decantatio...

The present invention relates to a short and industrially advantageous process for the preparation of Anagliptin.

The present invention relates to a pharmaceutical composition of NSAID and PPI or salts thereof. In particular, the invention relates to a composition of NSAID and PPI or salts thereof comprising a core and two or more layers coated on the core. The invention also includes a method of treating upper gastrointestinal...

A process for preparation of a compound of Formula (I) is disclosed.

The present invention relates to solid oral pharmaceutical compositions comprising cinacalcet or salts thereof. In particular, the present invention relates to solid oral pharmaceutical compositions comprising cinacalcet or salts thereof and at least one pharmaceutically acceptable excipient other than disintegratin...

The present invention relates to a process of preparing a pharmaceutical composition of NSAID and PPI or salts thereof. In particular, the invention relates to a composition of NSAID and PPI or salts thereof comprising a core and two or more layers coated on the core. The invention also includes a method of treating...

Pharmaceutical compositions comprising a beta-lactam compound selected from cefepime, sulbactam or a pharmaceutically acceptable derivative thereof, and a compound of Formula (I) or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.

The present invention provides a process for preparing a modified release solid oral pharmaceutical composition comprising cyclobenzaprine or salts thereof. In particular, the present invention relates to a process for preparing modified release solid oral pharmaceutical composition comprising a single unit of mini-...

The present invention provides a process for preparing a modified release solid oral pharmaceutical composition comprising cyclobenzaprine or salts thereof. In particular, the present invention relates to a process for preparing modified release solid oral pharmaceutical composition comprising a core comprising cycl...

The present invention provides a modified release solid oral pharmaceutical composition comprising cyclobenzaprine or salts thereof. In particular, the present invention relates to modified release solid oral pharmaceutical composition comprising a core comprising cyclobenzaprine or salts thereof and one or more rel...

A process for preparation of compound of Formula (I) is disclosed.

The present invention provides a modified release solid oral pharmaceutical composition comprising cyclobenzaprine or salts thereof. In particular, the present invention relates to a modified release solid oral pharmaceutical composition comprising a single unit of mini-tablet comprising cyclobenzaprine or salts the...

The present invention relates to a process for the preparation of Paliperidone palmitate comprises reaction of paliperidone and palmitoyl chloride in presence of an organic base.

The present invention relates to novel stable amorphous form of Vortioxetine Hydrobromide, has purity more than 99 % by HPLC. In present invention particular directs to process for the preparation of novel stable amorphous form of Vortioxetine Hydrobromide, has purity more than 99 % when measured by HPLC. ...

Pharmaceutical compositions comprising aztreonam or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

The present invention relates to a process for the preparation of intermediate of Nadifloxacin of Formula II: Formula II or a pharmaceutically acceptable salt thereof and its conversion to Nadifloxacin or its pharmaceutically acceptable salt.

Pharmaceutical compositions comprising ceftolozane or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

The present invention relates to process for the preparation of Teneligliptin or a pharmaceutically acceptable salt thereof, has purity more than 99% as measured by HPLC. The present invention particularly directs to an insitu process for the preparation of Teneligliptin or a pharmaceutically acceptable salt thereof...

The present invention provides a process for the preparation of 5-(4-(4-(5-cyano-1-tosyl-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide (tosyl Vilazodone)of formula V: Formula V or a pharmaceutically acceptable salt thereof and its conversion to Vilazodone or its pharmaceutically acceptable salt. ...

The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises less than of about 10% of plasticizing agent in coating. The inve...

The present invention relates to a process for the preparation of Dextromilnacipran or its salt thereof, which leads to develop industrially feasible simple and cost effective manufacturing process of Dextromilnacipran or its salt thereof with the higher purity and yield. In particular, the invention further provide...

The present invention relates to a process of preparation of Mirabegron intermediate. In the particular aspect of present invention relates to an improved process for the preparation of (R)-2-[2-(4-amino-phenyl)-ethylamino]-1-phenyl-ethanol, which is one of key intermediate for the preparation of Mirabegron. ...

The invention relates to a chewable tablet comprising sulpho-adenosyl-L-methionine (SAM-e) or a salt thereof. Said tablet composition comprises sulpho-adenosyl-L-methionine or a salt thereof; an alkalizing agent; a moisture repelling agent and one or more pharmaceutically acceptable excipients. The invention particu...

The invention relates to an oral liquid pharmaceutical composition comprising phenylephrine or a salt thereof in combination with one or more other pharmaceutical active agents with one or more antioxidant and one or more chelating agent. The invention further relates to use of such composition in the treatment of r...

Modified release pharmaceutical composition comprising glipizide or pharmaceutical acceptable salt thereof is disclosed. The modified release composition comprises drug layer and push layer with specific pharmaceutically acceptable excipients, wherein the said composition comprises a pharmaceutical acceptable excipi...

The specification discloses an amorphous form of valsartan disodium hydrate and process of preparation thereof.

The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salt thereof. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) for tablet coating. The in...

A process for preparation of compound of Formula (I) is disclosed.

ABSTRACT A process for preparation of compound of Formula (I) is disclosed.

The present invention provides a tablet dosage form comprising a) a layer, comprising a tablet of at least one active ingredient, inlayed in said layer with other pharmaceutically acceptable excipients; b) a layer comprising at least one active ingredient other than mentioned in (a) optionally with other pharmaceuti...

A process for preparation of a sodium salt of (2S, 5R)-2-carboxamido-7-oxo-6-sulfooxy-1,6-diaza-bicyclo[3.2.1]octane is disclosed.

Sodium salt of (2S, 5R)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxylic acid and a process for its preparation is disclosed.

The present application is to provide a process for the preparation of Lurasidone or pharmaceutically acceptable salt thereof. Further, it is to provide a process for the preparation of intermediate of Lurasidone hydrochloride by using green chemistry.

The present invention provides a stable amorphous Gatifloxacin and process for preparation. Further, it provides stable pharmaceutical compositions of amorphous Gatifloxacin along with other pharmaceutically acceptable excipient.

The present invention provides a process of preparing the solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a process of preparing multilayered coated pharmaceutical composition comprising at least two compartm...

The present invention relates to pharmaceutical compositions of topiramate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least two types of components, wherein at least one type of the component comprises a matrix of topiramate or salts t...

The present invention relates to modified release pharmaceutical compositions of cyclobenzaprine or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising unit dosage form of cyclobenzaprine or salts thereof in the form of uncoated units. The compositio...

The present invention relates to process for preparation of a pharmaceutical composition of mycophenolic acid or salts thereof. In particular, the present invention relates to a process of preparing the pharmaceutical composition comprising use of lactose and microcrystalline cellulose (MCC) in the ratio of amount o...

The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a pharmaceutical composition comprising metformin and sitagliptin or salts thereof which is devoid of any surface active agents. ...

The present invention provides process of preparing solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to process of preparing pharmaceutical composition comprising metformin and sitagliptin or salts thereof which ...

The present invention relates to a process for preparing modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least one immediate release and at least one extended release component...

The present invention relates to a process for the preparation a Key impurity of Lercanidipine and Nicardipine of formula II, which is pure: Formula II

The present invention relates to an in-situ process for DL-Epinephrine from N-benzyl adrenalone, which is finally resolved to provide R-(-)-L-Epinephrine, or an addition salt thereof. Further, it relates to preparation of N-benzyl adrenaline intermediate from N-benzyl adrenalone using readily available, inexpensive ...

The present invention relates to modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least one immediate release and at least one extended release component of methylphenidate or s...

The present invention relates to a modified release pharmaceutical composition of dexmethylphenidate or salts thereof. In particular, the present invention relates to a modified release pharmaceutical composition comprising plurality of components exhibiting both immediate and extended release of dexmethylphenidate ...

The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a multilayered coated pharmaceutical composition comprising at least two compartments of metformin or salts thereof exhibiting im...

The present invention relates to an improved process for the preparation Key intermediate of regadenoson, the compound of formula II. Formula II

The present invention relates to modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least one immediate release and at least one extended release component of methylphenidate or s...

The present invention relates to process for preparation of modified release pharmaceutical compositions of cyclobenzaprine or salts thereof. In particular, the present invention relates to process for preparing modified release pharmaceutical compositions comprising unit dosage form of cyclobenzaprine or salts ther...

The present invention relates to modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least one immediate release and at least one extended release component of methylphenidate or s...

The present invention relates to a process for the preparation of Linagliptin or a pharmaceutically acceptable slat thereof. Further aspects of the present invention relates to process for the preparation of Linagliptin key intermediate, having purity more than 98.0 %.

The present invention relates to a process for the preparation of modified release pharmaceutical compositions of dexmethylphenidate or salts thereof. In particular, the present invention relates to a modified release pharmaceutical composition comprising plurality of components exhibiting both immediate and extende...

The present invention relates to modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least one immediate release and at least one extended release component of methylphenidate or s...

The present invention relates to an oral pharmaceutical composition of mycophenolic acid or salts thereof. In particular, the present invention relates to the pharmaceutical compositions comprising lactose and microcrystalline cellulose (MCC), wherein the ratio of amount of lactose to MCC is in the range of about 1....

The present invention provides process of preparing solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to process of preparing pharmaceutical composition comprising metformin and sitagliptin or salts thereof which ...

The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a pharmaceutical composition comprising metformin and sitagliptin or salts thereof which is devoid of any glidant. The invention ...

The present invention relates to modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to a modified release pharmaceutical composition comprising plurality of components exhibiting both immediate and extended release of methylphenidate or salt...

The present invention relates to a process for preparing modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to a modified release pharmaceutical composition comprising plurality of components exhibiting both immediate and extended release of...

The present invention relates to modified release pharmaceutical compositions of methylphenidate or salts thereof. In particular, the present invention relates to modified release pharmaceutical compositions comprising at least one immediate release and at least one extended release component of methylphenidate or s...

The present invention relates to a process for preparing isolated impurity of Atovaquone, for example, O-methyl Atovaquone of Formula II, which is useful as reference marker. Formula II

The present invention relates to a process for preparation of delayed release pharmaceutical composition comprising less than of about 45% of mycophenolic acid or salts by total weight of composition and one or more pharmaceutically acceptable excipients. The invention also includes use of composition prepared by su...

The present invention provides a stable amorphous Regadenoson and process for preparation. Further, it provides stable pharmaceutical compositions of amorphous Regadenoson along with other pharmaceutically acceptable excipient.

The present invention provides a biphasic pharmaceutical composition comprising an insulin analogue, derivative or metabolite having isoelectric point between 5.8 to 8.5, zinc or salts thereof, isotonic agent optionally along with one or more pharmaceutically acceptable excipients, wherein the formulation exhibits a...

The present invention relates to an improved process for the preparation of Pidotimod, substantially free of impurities, to get high yield and purity.

The present invention relates to the process for the preparation isavuconazonium iodide hydrochloride, having purity more than 99%. A further aspect of the present invention relates to conversion of isavuconazonium iodide hydrochloride to isavuconazonium or a pharmaceutically acceptable salt thereof. ...

A method of treating bacterial infections in a diabetic subject, said method comprising administrating high dose of Cephalosporin antibacterial agent or pharmaceutical acceptable derivative thereof, wherein said Cephalosporin exhibits altered pharmacokinetic parameters in a diabetic subject. ...

The present invention provides a process For the Preparation of (10E)-10,11-didehydro-11-deoxy-6-O-methylerythromycin A. In particular aspect of present invention provides crystalline form of (10E)-10,11-didehydro-11-deoxy-6-O-methylerythromycin A. In further aspect of present provides the use of a crystalline form ...

The invention relates to a pharmaceutical composition comprising pidotimod or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients which provide desired storage stability. Further, the invention also provides process for preparing pharmaceutical composition of pidotimod or ...

Compounds of Formula (I), their preparation, and use in preventing or treating a bacterial infection are disclosed.

Compounds of Formula (I), their preparation, and use in preventing or treating a bacterial infection are disclosed.

The invention relates to a process for preparing pharmaceutical composition comprising pidotimod or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said invention provides stable pharmaceutical composition comprising pidotimod or pharmaceutically acceptable salt t...

The invention relates to a process for preparing liquid pharmaceutical composition comprising pidotimod or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The invention provides liquid pharmaceutical compositions having desired storage stability with improved taste fo...

The present invention relates to a process for preparing intermediates and impurities of Ropinirole or its pharmaceutically acceptable salt, for example, hydroxy and alkoxy-ropinirole of Formula II, which is useful as reference marker or a key intermediate to provide pure ropinirole. Formula II wherein R is h...

Compounds of Formula (I), their preparation, and use in preventing or treating a bacterial infection are disclosed.

Compounds of Formula (I), their preparation, and use in preventing or treating a bacterial infection are disclosed.

The present invention relates to an improved process for the preparation of substantially pure key intermediate of Teneligliptin, e.g. Boc-piperazine pyrazole having purity more than 99%. A further aspect of the present invention relates to conversion of Boc-piperazine pyrazole to Teneligliptin. ...

The present invention relates to an improved process for the preparation of substantially pure intermediate of Teneligliptin ,Tert-butyl-4-acetoacetylpiperazine-1-carboxylate or salt, having purity more than 99%. A further aspect of the present invention relates to conversion of said intermediate to Teneligliptin. ...

The present invention relates to a process for the preparation of Nimodipine intermediate, e.g. m-nitro arylidene or its salt thereof. In particular, of the present invention directs to process for the preparation of m-nitro arylidene, has purity more than 99 % when measured by HPLC. A further aspect of the present ...

This invention relates to a process of preparation of a pharmaceutical compositions comprising novel fixed dose combination of pharmaceutically effective amounts of pregabalin and nortriptyline or pharmaceutically acceptable salt or solvate thereof. Such novel pharmaceutical composition is useful for the treatment o...

The present invention relates to a fluidized bed based coating process for preparation of modified release multiparticulate systems. In particular, the fluidized bed based coating process relates to coating of multiparticulate system with a coating composition comprising poorly conducting and insulating material and...

The present invention relates to a modified release composition comprising multiparticulate systems of mesalamine. In particular, the invention relates to modified release composition comprising pellets of mesalamine coated with a composition comprising poorly conducting and insulating material and amorphous hydrate...

This invention relates to a pharmaceutical compositions comprising novel fixed dose combination of pharmaceutically effective amounts of pregabalin and nortriptyline or pharmaceutically acceptable salt or solvate thereof. Such novel pharmaceutical composition is useful for the treatment of neuropathic pain and relat...

The present invention provides a process For the Preparation of Sulfonamide Di-demethyl Azithromycin. In particular aspect of present invention provides crystalline form of Sulfonamide Di-demethyl Azithromycin. In further aspect of present provides the use of a crystalline form of Sulfonamide Di-demethyl Azithromyci...

The present invention relates to a process for the preparation of Paliperidone palmitate free from its impurities comprises reaction of paliperidone and palmitic acid in presence of DCC  DMAP and chlorinated solvent.

The present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof. In particular, the present invention relates to solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, d...

The present invention relates to process of preparing pharmaceutical compositions of tamsulosin or salts thereof. In particular, the invention relates to process of preparing pharmaceutical compositions comprising a core of tamsulosin or salts, hydrates thereof and at least one specialized coating over the core. Suc...

The present invention relates to pharmaceutical compositions of tamsulosin or salts thereof. In particular, the invention relates to pharmaceutical compositions comprising a core of tamsulosin or salts, hydrates thereof and at least one specialized coating over the core. Such compositions of tamsulosin may exhibit d...

The present invention relates to novel stable amorphous form of Isavuconazole base, having purity more than 90 %. In particular of the present invention relates to process for the preparation of novel stable amorphous form of Isavuconazole base, having purity more than 90 %.

The invention relates to fixed dose pharmaceutical compositions comprising paracetamol, dicyclomine or pharmaceutically acceptable salt thereof and effervescent agent along with one or more pharmaceutically acceptable excipients to improve dissolution profile of these active ingredients and also discloses process of...

The present invention relates to a pharmaceutical composition of NSAID and PPI or salts thereof. In particular, the invention relates to a composition of plurality of components of NSAID and PPI or salts thereof. The invention also includes a process of preparing such compositions and method of treating upper gastro...

The present invention relates to a pharmaceutical composition of NSAID and PPI or salts thereof. In particular, the invention relates to a composition of NSAID and PPI or salts thereof comprising a core and two or more layers coated on the core. The invention also includes a process of preparing such compositions an...

The present invention relates to novel stable polymorphs of Isavuconazole base, having purity more than 95% when measured by HPLC. In particular, of the present invention directs to crystalline form Isavuconazole Hydrobromide salt, having purity more than 95% when measured by HPLC.

The invention relates to process for preparing fixed dose pharmaceutical compositions comprising paracetamol, dicyclomine or pharmaceutically acceptable salt thereof and effervescent agent along with one or more pharmaceutically acceptable excipients to improve dissolution profile of these active ingredients. ...

This invention relates to a process of preparing solid pharmaceutical compositions comprising metformin or pharmaceutically acceptable salt thereof. The composition of the invention comprises a solid dosage form which provides sustained release of the metformin. The invention also includes method of treating type-2 ...

This invention relates to a solid pharmaceutical compositions comprising metformin or pharmaceutically acceptable salt thereof. The composition of the invention comprises a solid dosage form which provides sustained release of the metformin. The invention also includes a process of preparing such compositions and me...

The invention relates to a process of preparing a pharmaceutical composition comprising of bepotastine or pharmaceutically acceptable salt thereof, wherein the said composition is formulated as nasal spray or nasal drop.

The invention relates to a pharmaceutical composition comprising of bepotastine or pharmaceutically acceptable salt thereof, wherein the said composition is formulated as nasal spray or nasal drop.

The invention relates to a pharmaceutical composition comprising bepotastine or pharmaceutically acceptable salt thereof, decongestants and/or cortiocosteroids and at least one pharmaceutically acceptable excipient, wherein the composition is formulated as nasal spray or nasal drop.

The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular present invention relates to a coated pharmaceutical composi...

The present invention relates to a process for preparing key intermediate of Linagliptin which involves condensation of 8-Bromo Xanthine compound with 3-(R)-Boc aminopiperidine using an organic base such as diisopropyl ethyl amine in presence of a solvent.

It may be one of the aspects of the invention that a drug delivery device for delivery of two or more independently user selectable multiple doses of medicaments contained in separate cartridges of the medicament reservoirs within a single device operatively connected to a single dispense interface which may be ope...

The present invention relates to an improved process for preparing Fosaprepitant dimeglumine having purity greater than 99.5% by the reaction of dibenzyl ester of Fosaprepitant with N-methyl D-glucamine using catalyst such as Pd/C in presence of aqueous medium.

A process for preparation of sodium salt of trans-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]-octane-2-carbonitrile (Formula (I)) has been disclosed.

A process for preparation of trans-sulfuric acid mono-[2-(N’-[(R)-piperidin-3-carbonyl]-hydrazinocarbonyl)-7-oxo-1,6-diaza-bicyclo[3.2.1]oct-6-yl]ester (Formula (I)) has been disclosed.

Abstract The present invention relates to orally disintegrating pharmaceutical compositions comprising Tapentadol or salt thereof. The present invention also relates to a process for the preparation of orally disintegrating pharmaceutical composition of Tapentadol or salt thereof along with taste masking agent an...

Abstract The present invention provides an oral pharmaceutical composition comprising plurality of units of dabigatran etexilate or salts thereof. By providing such composition which begins to release organic acid before the release of dabigatran or salts thereof, it is possible to reduce interpatient variability t...

Abstract The present invention relates to stable oral pharmaceutical compositions of cefixime or salts thereof. The composition comprises of intermediates of cefixime or salts thereof with one or more hydrophobic substances. The intermediates as disclosed in the present invention are prepared by compaction of cefix...

Abstract The present invention relates to process for preparation of orally disintegrating pharmaceutical compositions comprising Tapentadol or salt thereof. The present invention also relates to a process for the preparation of orally disintegrating pharmaceutical composition of Tapentadol or salt thereof along ...

Abstract The present invention provides an oral pharmaceutical composition comprising plurality of pellets of dabigatran etexilate or salts thereof and plurality of pellets of organic acid. By providing plurality of pellets of dabigatran etexilate or salts thereof and plurality of pellets of organic acid it is poss...

Abstract The present invention relates to improved orally disintegrating compositions of phentermine or salts thereof. The invention describes orally disintegrating compositions comprising granules of phentermine or salts thereof and at least one organic acid, wherein the granules are prepared by wet granulation ...

The present invention relates to a process for preparing dehydroatovaquone of Formula II, which is useful as intermediate and reference marker for atovaquone. Formula II

The invention provides a method of assembling a device and a kit suitable for administration to multiple patients a multi-dose pharmaceutical composition of nasal analgesic in the form of a nasal spray. The present invention also provides a method for reducing the respiratory depressant effect associated with diamor...

Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) sulbactam or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutica...

The invention relates to an oral pharmaceutical composition and more particularly relates to taste masked oral pharmaceutical compositions of metformin or pharmaceutically acceptable salt or solvate thereof. The invention also includes a process of preparing such compositions and method of treating type-2 diabetes m...

The invention relates to a process of preparing an oral pharmaceutical composition and more particularly relates to taste masked oral pharmaceutical compositions of metformin or pharmaceutically acceptable salt or solvate thereof. The invention also includes a method of treating type-2 diabetes mellitus by administe...

A topical pharmaceutical composition comprising a combination of nadifloxacin, mometasone and terbinafine or pharmaceutically acceptable salt thereof is provided. A method for treatment of mixed infections and dermatitis using pharmaceutical composition comprising combination of nadifloxacin, mometasone and terbinaf...

This invention relates to a process of preparing a stable oral pharmaceutical compositions comprising Isavuconazonium or pharmaceutically acceptable salt thereof. By using such novel composition, treatment of aspergillosis, mucormycosis and related fungal disorders is possible.

A topical pharmaceutical composition comprising a combination of nadifloxacin, mometasone and terbinafine or pharmaceutically acceptable salt thereof is provided. A method for treatment of mixed infections and dermatitis using pharmaceutical composition comprising combination of nadifloxacin, mometasone and terbinaf...

This invention relates to a stable oral pharmaceutical compositions comprising Isavuconazonium or pharmaceutically acceptable salt thereof. The invention also discloses methods of preparing such antifungal pharmaceutical compositions.

Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) at least one beta-lactam antibiotic or a pharmaceutically acceptable salt thereof, (b) sulbactam or a pharmaceutically ac...

The invention relates to pharmaceutical or nutritional multivitamin composition. More particularly, the invention relates to moisture stabilized composition of multivitamin with L Carnitine in pure base form.

The invention relates to a process of preparing pharmaceutical or nutritional multivitamin composition. More particularly, the invention relates to moisture stabilized composition of multivitamin with L Carnitine in pure base form.

The present invention relates to a process for preparing Oxo-Ropinirole or pharmaceutically acceptable salt thereof by oxidation of ropinirole or pharmaceutically acceptable salt thereof with Jones reagent in presence of a solvent to provide Oxo ropinirole having purity greater than or equal to 95 %. ...

ABSTRACT The present invention relates to a process for preparing impurity of Esomeprazole or its pharmaceutically acceptable salt, for example, N-methyl esomeprazole of Formula IIa and IIb, which is useful as reference marker or a key intermediate to quantify its presence in Esomeprazole. Formula IIa F...

The present invention relates to solid oral modified-release composition comprising oxcarbazepine or salts thereof. In particular, the present invention relates to solid oral modified-release compositions comprising a core of oxcarbazepine or salts thereof coated with a functional coating. Preferably, the compositio...

The present invention relates to a process for preparing the compound of 3-((4-hydroxybenzamido)methyl)-5-methylhexanoic acid of Formula II or its salt, which is useful as reference marker or a key intermediate to provide pure pregabalin. Formula II

The present invention relates to pharmaceutical compositions comprising novel combination of roflumilast and acebrophylline. In particular, the present invention relates to pharmaceutical compositions comprising roflumilast or salts thereof and acebrophylline or salts thereof and its use in treating chronic obstruct...

The present invention relates to a process for the preparation of Fesoterodine from 5-hydroxy methyl Tolterodine by using a mixture of organic solvents to reduce the formation of structural related impurities in Fesoterodine or its pharmaceutically acceptable salt.

The present invention relates to an improved process for the preparation of intermediate of Lorcaserin, N-(4-chlorophenethyl)-2-chloropropan-1-amine or salt thereof, in high yield under mild reaction conditions, has purity more than 98%. A further aspect of the present invention relates to conversion of propyl chlor...

There is provided a stabilized injectable pharmaceutical composition of epinephrine or salts thereof comprising sodium metabisulfite  wherein the ratio of the amount of epinephrine or salt thereof to sodium metabisulfite in the composition ranges from about 1:0.005 to about 1:1.5 by weight. It has been observed that...

The present invention relates to substantially pure N-Methyl-N-[2-(4-aminophenoxy) ethyl]-4-aminophenethylamine (referred herein after “Dofetilide triamine intermediate”) or its salt thereof, has mono-nitro amine impurity less than 0.5 % when measured by HPLC. In particular aspect of present invention provides an im...

The present invention relates to a process for the preparation of Ziprasidone or its pharmaceutically acceptable salt free from its impurities  for example  Oxindole  comprises dissolving Crude Ziprasidone in a mixture of water and isopropyl alcohol and isolating Pure Ziprasidone or pharmaceutically acceptable salt....

The present invention provides a process for the removal of residue on ignition by the use of nanofiltration technique during the process of preparation of active pharmaceutical ingredient (API). The active pharmaceutical ingredient (API) includes of ropinirole, trauxrutin, fexofenadine, ioversol and iohexol and its...

ABSTRACT The present invention relates to an improved process for the preparation of pramipexole or its salt, which avoids or reduces the formation of impurities. The present invention particularly relates to an improved process to provide pramipexole or its salt having impurity C less than or equal to 0.15%. ...

There is provided pharmaceutical microparticulate compositions of biologically active polypeptides and methods of forming and using such compositions. More particularly, microparticle compositions for sustained release of biologically active polypeptides are provided. Compositions of biologically active polypeptides...

The present invention provides Salmeterol Impurity G, process for preparing and isolating thereof. In further aspect of present provides the use of a Salmeterol Impurity G as reference markers and/or reference standards during the synthesis of Salmeterol or its pharmaceutically acceptable salt thereof. ...

A solid pharmaceutical composition comprising mefenamic acid and dicyclomine or a salt thereof is disclosed. The said invention is used in the treatment of pain.

The present invention relates to crystalline form of Lorcaserin Hydrochloride. In particular, of the present invention directs to process for the preparation of crystalline form of Lorcaserin Hydrochloride, has purity more than 99 % when measured by HPLC.

The present invention relates to an improved pharmaceutical compositions of diclofenac or pharmaceutically acceptable salt and pharmaceutically acceptable excipients wherein the composition is substantially free of dispersing agents. By judicially using pharmaceutical excipients other than dispersing agent  pharmace...

The present invention relates to solid oral modified-release composition comprising budesonide or salts thereof. In particular, the present invention relates to solid oral modified-release composition comprising matrix of budesonide or salts thereof with one or more lipophilic excipients and one or more hydrophilic ...

There is provided pharmaceutical microparticulate compositions of biologically active polypeptides and methods of forming and using such compositions. More particularly, microparticle compositions for sustained release of biologically active polypeptides are provided. By using particular pharmaceutical excipients, c...

Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.

The present invention relates to a process of preparing novel tablet dosage forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer that includes a tablet of one or more active pharmaceutical ingredien...

The present invention provides a ready-to-use pharmaceutical composition comprising: (a) insulin glargine, (b) Gly(A21), Lys(B28), Pro(B29) human insulin, (c) about 0.2mg/ml to about 10mg/ml of glycine, and (d) a pharmaceutically acceptable excipient.

Compounds of Formula (I)  their preparation and use in preventing or treating bacterial infections are disclosed.

The present invention relates to a process for the preparation of Vilazodone or its pharmaceutically acceptable salt. The present invention particularly relates to a process for the preparation of Vilazodone or its pharmaceutically acceptable salt by using water and nitrile solvent to provide greater yield and purit...

Pharmaceutical compositions comprising: (a) at least one antibacterial agent selected from cefixime, cefpodoxime, ceftibuten, cefuroxime or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed. ...

The present invention relates to process of preparing a solid oral modified-release composition comprising budesonide or salts thereof. In particular, the present invention relates to solid oral modified-release composition comprising matrix of budesonide or salts thereof with one or more amphiphilic excipients and ...

The present invention relates to an improved process for preparing 3-dimethylaminomethyl-5-methyl-hexan-2-one, which is one of the key starting material in the preparation of tetrabenazine. The present invention also provides improved process for preparation of tetrabenazine. The product 3-dimethylaminomethyl-5-meth...

Compounds of Formula (I)  their preparation and use in preventing or treating bacterial infections are disclosed.

The present invention relates to a process of preparing solid oral modified-release composition comprising budesonide or salts thereof. In particular, the present invention relates to solid oral modified-release composition comprising matrix of budesonide or salts thereof with one or more lipophilic excipients and o...

Pharmaceutical compositions comprising cefepime or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

The present invention provides a process for the preparation of Fesoterodine or its pharmaceutically acceptable salt, which comprises reaction of 5-hydroxy methyl Tolterodine with isobutyryl chloride in absence of base in organic solvents to provide Fesoterodine.

There is provided pharmaceutical microparticulate compositions of biologically active polypeptides and methods of forming and using such compositions. More particularly, a compositions for sustained release of biologically active polypeptides containing more than 5% w/w of sugar are provided. By using more than 5% w...

The present invention relates to a novel process for preparing the impurities of Cefuroxime Axetil. More particularly the present invention relates to a novel process for preparing Cefuroxime Axetil a, ß sulfoxides impurities and its use as a reference standard

The present invention relates to anhydrous crystalline form of Apixaban. In particular, of the present invention directs to process for the preparation of anhydrous crystalline form of Apixaban, has purity more than 99 % when measured by HPLC.

The present invention relates to a process for the preparation of Levofloxacin hemihydrate. Further  the present invention relates to a process for the purification of Levofloxacin hemihydrate to afford more than or equal to 99.5% by using methanol  dichloromethane and water.

Compounds of Formula (I), their preparation, and use in preventing or treating a bacterial infection are disclosed.

A stable pharmaceutical composition comprising mometasone or a salt thereof in the form of emulsion, the said composition is used in the treatment of skin diseases.

The present invention relates to a process for the preparation of Dabigatran etexilate free base from the salt of Dabigatran etexilate using base, and a process for the preparation of its substantially pure Form I.

Pharmaceutical compositions comprising sulbactam or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.

The present invention relates to novel tablet dosage forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer that includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in...

Pharmaceutical compositions comprising sulbactam or a pharmaceutically acceptable derivative thereof, and imipenem or a pharmaceutically acceptable derivative thereof are disclosed.

The invention relates to a process to prepare pharmacologically active phosphoric acid mono-(1-{4-[(S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,6-difluoro phenyl}-4-methoxy methyl-piperidin-4-yl) ester.

The present invention provides a process for preparation of repaglinide wherein the said process comprising, a) reacting 4-(carboxymethyl)-2-alkoxybenzoic acid with (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine in organic solvent, optionally in presence of base, b) isolating repaglinide from reaction mass there...

The present invention relates a process for the preparation of Cinacalcet or its pharmaceutically acceptable salt  which comprises reductive amination of 3-[3-(trifluoromethyl)phenyl]propionaldehyde by reaction with (R)-(1-naphthyl)ethylamine using a reducing agent in presence of zinc salt and alcohol. ...

The invention relates to ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing m...

The present inventors while developing the processes for the preparation of entacapone have developed process for the preparation of entacapone Morph –D from any polymorphic form or their mixture it has the advantage of (i) use of water as the solvent in the presence of readily available organic or inorganic bases (...

A stable aqueous insulin preparation comprising human insulin, analogues or derivatives thereof, one or more solubility enhancing agents are selected from urea, amino acids and/or surfactants optionally one or more other pharmaceutically acceptable excipient(s).

The present invention relates to a stable pharmaceutical composition of saxagliptin or salts thereof. In particular  the invention relates to stable comprises a core and two or more layers coated on the core  wherein the inner first coat is free of polyvinyl alcohol. Such composition of saxagliptin may exhibit relat...

The present invention relates to a stable pharmaceutical composition of Sodium oxybate or free base thereof. The invention relates to pharmaceutical composition of sodium oxybate comprising sodium oxybate and one or more preservative(s) and optionally other pharmaceutically acceptable excipients. Such compositions c...

The present invention relates to a stable pharmaceutical composition of saxagliptin or salts thereof. In particular, the invention relates to composition comprising plurality of saxagliptin components. Such composition of saxagliptin exhibit relatively improved storage stability and particularly, levels of degradant...

The present invention relates to a stable pharmaceutical composition of saxagliptin or salts thereof. In particular  the invention relates to stable comprises a core and two or more layers coated on the core  wherein the inner first coat is free of polyvinyl alcohol. Such composition of saxagliptin may exhibit relat...

A solid oral dosage form of itraconazole or salt thereof comprising an inert core wherein the said inert core has a particle size between 25# to 40#.

The present invention provides agents having high antimicrobial activity for preventing and treating infectious diseases. Thus, the present invention provides novel cyano-(substituted)-methylenepiperidinophenyl oxazolidinone derivatives, processes for making the compounds, as well as antimicrobial compositions conta...

The present invention relates to a novel process for the manufacture of blood-platelet aggregation inhibiting agent. In particular, the present invention is directed to a process for the manufacture of Methyl-(+)-(S)-&agr;-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-S-(4H)acetate bisulfate Form-I. ...

N/A

The present invention provides an inlay tablet dosage form comprising a) an inner inlayed tablet comprising of misoprostol or pharmaceutically acceptable salts thereof along with other pharmaceutically acceptable excipients b) an outer tablet comprising of coated beads of diclofenac or pharmaceutically acceptable sa...

The present invention provides an orally dissolving pharmaceutical composition in the form of film or strips, comprising rhein or diacerein, or salts or esters or prodrug thereof, along with one or more pharmaceutically acceptable excipients. The invention also relates to the process of preparation of such compositi...

The present invention provides an orally disintegrating pharmaceutical composition, in the form of tablet comprising rhein or diacerein, or salts or esters or prodrug thereof, along with one or more pharmaceutically acceptable excipients. The invention also relates to the process of preparation of such compositions....

Needle shield is provided over the needle in a pre filled syringe containing pharmaceutical substance as a safety precaution to prevent any hurt or injury to the patient while using the syringe. If there is a repetitive self administration of the pharmaceutical substance by the patient it requires frequent handing o...

The present invention relates to the family of substituted biaryl oxazolidinones having antimicrobial activity. The invention also relates to pharmaceutical compositions containing the compounds and to methods for treating or preventing microbial infections using the compounds of present invention. ...

The present invention relates to pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof having average particle size from about 0.1 microns to 30 microns, preferable from 0.1 microns to 0.20 microns which are bioequivalent to a 50 mg diacerein formulation currently marketed...

The present invention provides a method of treatment of osteoarthritis composing administering 20mg to 45mg of rhein or diacerein, or salts or esters or prodrugs thereof to a patient, in a dosage form twice daily from day one of the therapy.

The present invention relates to a process for commercial production of octreotide using solution peptide chemistry and inexpensive amino acid derivatives. Thus the hexapeptide (Boc) D-Phe-Cys(Acm)-Phe-D-Trp-Lys(Boc)-Thr-OMe is synthesised by condensation of two tripeptide fragments, saponified and condensed with Cy...

The present invention provides a tablet dosage form comprising a) a layer, comprising a tablet of at least one active ingredient, inlayed in said layer with other pharmaceutically acceptable excipients; b) a layer comprising at least one active ingredient other than mentioned in (a) optionally with other pharmaceuti...

This invention discloses novel prepro-insulin polypeptides. The polypeptides consist of an N-terminal region, derived from N-terminal regions of secretory proteins, and a downstream insulin polypeptide region. The N-terminal region directs the polypeptides efficiently into the secretory pathway of yeasts. Modificati...

The present invention relates to the family of substituted biaryl oxazolidinones having antimicrobial activity. The invention also relates to pharmaceutical compositions containing the compounds and to methods for treating or preventing microbial infections using the compounds of present invention. ...

The present invention provides a tablet in tablet dosage form comprising a) an inner tablet comprising of duloxetine or salts thereof along with other pharmaceutically acceptable excipients b) an outer tablet comprising of inert pharmaceutically acceptable excipients. Duloxetine is a selective serotonin and norepine...

The present invention related to a pharmaceutical composition comprising coated beads of duloxetine or salt thereof along with stabilizer and one or more pharmaceutically acceptable excipients.

The prsent invention of a capsule form comprising duloxetine or salt thereof along with other pharmaceutically acceptable excipients, wherein capsule is coated with pharmaceutically acceptable enteric coat.

The present invention relates to a pharmaceutical composition comprising uncompressed coated beads of duloxetine or salt thereof substantially free of stabilizer along with pharmaceutically acceptable excipients, wherein the coated beads of duloxetine or salt thereof are coated with enteric polymer other than hydrox...

The present invention provides a pharmaceutical composition comprising duloxetine or salt thereof conjugated to ion exchange resin particles optionally along with other pharmaceutically acceptable excipients.

The present invention of a process for preparation of 2-bromo-4,5-difluoroaniline compound of formula III. The process comprising, a) brominating 3,4 difluroaniline of formula II in presence of potassium carbonate and mathylene, at a temperature of – 40 C to – 50 C, to obtain a compound of formula III. ...

The present invention provides a machine for the manufacture of tablet wherein the tablet comprises a bilayer tablet. The machine comprises positioning feed frame assembly first layer, positioning Feed frame assembly second layer, positioning powder scraper blade, positioning vacuum supply, positioning two sensor de...

The invention provides a process for obtaining a precursor for insulin, analogs or derivatives thereof having correctly bonded cystine bridges. The process involves solubilizing inclusion bodies in a solution containing both cysteine or cysteine hydrochloride and urea followed by reverse dilution. ...

The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infectious. Thus, the present invention provides novel oxazolidinone derivatives, processes for making compounds as well as antimicrobial pharmaceutical compositions containing said derivat...

The present invention relates to efficient process for (0-B)-Diacetoxy-(8,9-difluoro-6,7-dihydro-1-oxo-1H,5H-benzo[ij] quinolizine-2-carboxy) borane, and to their application in the synthesis of Nadifloxacin and its enantiomers, salt and prodrug thereof.

The present invention provides a bilayered tablet dosage form comprising a) first layer, which further comprises of tablet of diclofenac or salts thereof optionally coated with enteric polymer, inlayed in said layer along with inert pharmaceutically acceptable excipients b) the second layer comprises of misoprostol ...

The present invention relates to a test device and a method for the determination of minimum inhibitory concentration of an antimicrobial agent. The invention also relates to producing predefined concentration gradients of chemically and biologically active ingredients on a porous carrier.

The present invention relates to the extraction and isolation of insulins from recombinant sources, particularly those expressed in and secreted by yeasts. Organic solvents have been used to extract host surface bound forms of insulin polypeptide. In addition, procedures for combining the steps medium clarification...

A pharmaceutical composition comprising two distinctive layers wherein first layer comprises of (A) a therapeutically effective amount of decongestant or a pharmaceutically acceptable salt, solvate or derivatives thereof alongwith at least one carrier material comprising a mixture of (a) at least one controlled ...

There is provided a supersaturable self-emulsifying drug delivery system comprising rhein or diacerein, or salts, or esters, or prodrug thereof optionally with one or more pharmaceutically acceptable excipients. 18

The present invention provides a device for the delivery of biological material across the biological tissue with minimal or no pain, damage and irritation to the tissue. The device comprises one microneedle attached to a needle cap. 6 JUN 2008 8

The present invention provides a device for the programmed delivery of biological material across the biological tissue. The device comprises two reservoirs one of which delivers the biological material of immediate nature and the other reservoir delivers the biological material whose delivery is intended to be deli...

A device for delivery of biodegradable microneedle across a biological barrier, wherein the device comprises a microneedle strip comprising of biodegradable microneedle, and a mechanism to cut the selected portion of microneedle strip corresponding to the selected dose of the biodegradable microneedle to be delivere...

The invention relates to processes for the preparation of pure zoledronic acid or pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions that include the pure zoledronic acid.

The present invention provides ophthalmic formulations or vehicle solutions, which are administrable as liquids and which gels upon instillation into the eye comprising ophthalmic pharmaceutically active agent, combination of gellan gum" and polyvinyl pyrrolidone optionally with other ophthalmically acceptable carri...

The invention relates to processes for the preparation of anhydrous azithromycin. The invention also relates to a one-pot process for the preparation of azithromycin without isolation of intermediates. The invention also relates to pharmaceutical compositions that include the anhydrous azithromycin or a pharmaceutic...

The invention provides an insulin analog protamine crystals comprising human insulin analog, zinc ions, protamine and one or more ligand selected from group consisting of benzyl alcohol, phenylethanol, phenoxyethanol, benzoic acid, mandelic acid, 2,2,2 trifluro-1-phenyl alcohol, phenylphosphonic acid and derivatives...

The present invention provides a process for preparation of pure azithromycin, wherein the impurity level is below 0.3%.

The invention provides the process for purification of chlorothiazide sodium by treating chlorothiazide with sodium source in methanol. The process involves the formation of chlorothiazide sodium methanol solvate and converting the solvate into chlorothiazide sodium.

The invention provides process for the preparation of chlorothiazide or salt thereof which is very simple and easily scalable at commercial scale. The process of invention is provides enhanced yield and purity of chlorothiazide and salts thereof. 118 JUL 2008 10

The present invention provides simple purification process of Diacerein to keep the level of aloemodine content below 2ppm. The diacenen obtained by the process of present invention where used for making various pharmaceutical acceptable compositions.

The present invention relates to pharmaceutical compositions comprising about 44 mg of rhein or diacerein, or salts or esters or prodrugs thereof having average particle size from about 0.1 microns to 30 microns, preferable from 0.1 microns to 0.20 microns which are bioequivalent to a 50 mg diacerein formulation cur...

The invention provides a process for obtaining a precursor for insulin, analogs or derivatives thereof having correctly bonded cystine bridges. The process involves solubilizing inclusion bodies in a solution containing higher concentration of protein, cysteine or cysteine hydrochloride and one or more chaotropic au...

The present invention provides an immediate release wet granulated pharmaceutical composition comprising from about 20 mg to about 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof, wherein the composition exhibits no significant difference in rate and/or an extent of absorption of the rhein or dia...

The invention provides a process for preparation of substituted 3-aryloxy propane derivatives. It further provides its characterization by spectral analyses such as IR, NMR and mass.

The present invention provides a device for the delivery of biological material across the biological tissue. The device comprises of an extender which when attached to a needle hub of a needle assembly allows protrusion of desired length of needle from the distal end of the extender.

The present invention provides a pharmaceutical composition comprising eszopiclone or salt thereof along with cyclodextrins or derivatives thereof and one or more pharmaceutically acceptable excipients. 111 JUL20Q* 10

The present invention relates to novel polymorphs S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-l-yl)-5-methyl-l-oxo-lH,5H-benzo[i,j]quinolizine-2-carboxylic acid lysine salt. The invention also relates to the novel process for the preparation of the polymorphs. The invention further provides pharmaceutical compo...

The present invention provides a pharmaceutical composition comprising rhein or diacerein or salts thereof adsorbed on a pharmaceutically acceptable adsorbent optionally with one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions. The comp...

The present invention provides a melt granulated pharmaceutical composition comprising rhein or diacerein, or salts thereof optionally with one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions. The composition of the present invention ma...

The present invention provides an immediate release wet granulated pharmaceutical composition comprising of rhein or diacerein, or salts thereof optionally with one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such compositions. The composition of the...

The present invention provides a self-emulsifying drug delivery system comprising rhein or diacerein, or salts thereof optionally with one or more pharmaceutically acceptable excipients. The composition of the present invention may exhibit improved bioavailability along with reduced undesirable side effects. ...

The present invention provides a pharmaceutical composition comprising rhein or diacerein, or salts thereof along with water-soluble cyclodextrins or derivatives thereof optionally with one or more pharmaceutically acceptable excipients. The invention also relates to processes for the preparation of such composition...

A single oral dose pharmaceutical composition comprising, triple combination of entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts thereof along with other pharmaceutically acceptable excipients, wherein a "substantial portion" of entacapone or pharmaceutically acceptable salts thereof is separ...

The present invention provides a single oral dose monolayered tablet pharmaceutical composition comprising, triple combination of entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts thereof along with other pharmaceutically acceptable excipients, wherein a "substantial portion" of entacapone or ...

The present invention provides a process for the preparation of stable polymorphic form-D of (E)-Entacapone, wherein the said process comprises of a) reacting 3,4-dihydroxy-5-nitrobenzaldehyde with 2-cyano-N,N-diethyl acetamide in alcohol solvent in presence of base b) isolating the stable polymorphic form-D of (E)-...

The present invention provides a single oral dose bilayered tablet pharmaceutical composition comprising, triple combination of entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts thereof along with other pharmaceutically acceptable excipients, wherein a "substantial portion" of entacapone or ph...

The present invention provides a pharmaceutical composition that comprises of pre-coated clopidogrei or salts thereof along with other pharmaceutically acceptable excipients. Clopidogrei or salts thereof may be present as powder, granules, microgranules, particulate form, pellets, micropellets and minitablet. ...

Present invention describes a process for the preparation of N-methyl-3- [(4-trifluoromethyl) phenoxy]-3-phenylpropylamine i.e. Fluoxetine Hydrochloride Form-A.

A process for preparation of 4-(carboxymethyl)-2-ethoxybenzoic acid of formula-II, an intermediate useful in the preparation of repaglinide wherein the said process comprising, a) reacting the compound of formula-III with base in solvent, b) isolating 4-(carboxymethyl)-2-ethoxybenzoic acid from reaction mass thereof...

The present invention provides a process for the preparation of stable polymorphic form-D of entacapone, wherein the said process comprising a) adding entacapone to dimethyl acetamide, b) isolating and drying the polymorphic form-D of Entacapone from reaction mass thereof.

A pharmaceutical composition comprising entacapone or salt thereof along with wetting agent and one or more pharmaceutically acceptable excipients.

The 4-(((S)-3-methyl-1-(2-(piperidin-1yl)phenyl)butylcarbamoyl)methyl)-2-ethoxy-N-((S)-3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)benzamide of formula-II

This invention describes the use of pharmaceutical composition, which comprise three components of which at least one is a slow release therapeutic agent. Such useful compositions are applicable for the tratment of humans suffering form diabeic, hypertensive, cardiovascular, hyperlipidemic conditions and their assoc...

The present invention provides a pharmaceutical composition comprising entacapone or salt thereof along with cyclodextrins or derivatives thereof and one or more pharmaceutically acceptable excipients.

N/A

The instant invention relates to novel prodrugs of optically pure benzoquinolizine-2-carboxylic acid, and pharmaceutical compositions that include the prodrugs. In particular, the present invention relates to the sulfonic acid salt of L-alanine and L-valine prodrugs of s- (-) -9- fluoro 6,7-dihydro-8- (4-hydroxypipe...

The present invention relates to melt granulated pharmaceutical compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50. The composition exhibits no variability in fed as compared to fasted state conditio...

The present invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The composition exhibits no variability in fed as compared to fasted ...

The present invention provides a pharmaceutical composition comprising 20 to 45 mg of rhein or diacerein, or salts or esters or prodrugs thereof, characterized in that said composition exhibits at least 20% reduction in soft stool effect as compared to a 50 mg diacerein formulation marketed under the trade name Art ...

The present invention provides system for delivering erythropoietin, its analogue or derivatives thereof comprising a pen shaped injection device primarily for self administration by people suffering from diseases for which erythropoietin is indicated.

The present invention provides a system of precise delivery of insulin. Diabetics require several doses of insulin injections during the course of the day. The required insulin regimen varies from patient to patient and depends on the type of insulin to be injected (slow, medium, fast acting, or specific combination...

The invention relates to crystalline and amorphous polymorphs of S-(-)-9-fiuoro-6,7-dihydro-8-(4-L-alaninyloxypiperidin-1 -yl)-5-methyl-1 -oxo-1 H,5H-benzo[ij ] quinolizine-2-carboxylic acid methanesulfonic acid salt and its pharmaceutical compositions. The polymorphs and compositions of the invention are useful to ...

The invention provides a process for obtaining a precursor for insulin, analogs or derivatives thereof having correctly bonded cysteine bridges. The process involves solubilizing inclusion bodies in a solution containing both cysteine or cysteine hydrochloride and urea followed by reverse dilution. ...

The invention provides a signal oral dose pharmaceutical composition comprising, triple combination of entacepone, levodapa and carbidopa, or salts thereof along with one or more sugar alcohols wherein entacapone is co-micronized with sugar alcohol, characterized in that one or both of the rate and the absorption of...

The invention provides a signal oral dose pharmaceutical composition comprising, triple combination of entacepone, levodapa and carbidopa, or pharmaceutically acceptable salts thereof along with one or more sugar alcohols wherein entacapone is co-micronized with sugar alcohol. The invention also provides process of ...

The present invention provides a pharmaceutical composition comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols where entacapone is co-micronized with sugar alcohol. The invention also provides process of making such compositions.

The present invention provides a single oral dose pharmaceutical composition comprising triple combination of entacapone, levodopa and carbidopa, or salts thereof and microcrystalline cellulose in an amount of at least 5% by weight of the composition along with other pharmaceutically acceptable excipients. ...

The present invention relates to an improved process for the preparation of extremely pure l-(4’-Fluorophenyl)-l-(3-dimethylaminopropyl)-5-phthalanecarbonitrile and its bromide salt (Citalopram hydrobromide), which is a well known antidepressant. Other aspect of the invention are isolation of crystalline (4-Bromo-2-...

The present invention provides a method for treating a resistant bacterial infections caused by ESBLs producing strain in a subject in need thereof, which comprises a) administering a pharmaceutical dosage form comprising cefepime in combination with sulbactam and pharmaceutically acceptable excipients via parenter...

The present invention of a pharmaceutical composition comprising duloxetine or salts thereof along with polyethylene glycol (PEG) and one or more pharmaceutical acceptable exipients.